CARTESIAN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.72 USD | +10.43% |
|
+41.31% | +67.88% |
| May. 24 | Mizuho Securities Starts Cartesian Therapeutics With Buy Rating | MT |
| May. 22 | Cartesian Gets Regenerative Medicine Advanced Therapy Label for Myasthenia Gravis Drug Candidate | MT |
Financials (USD)
| Sales 2024 * | 14.9M | Sales 2025 * | 9.95M | Capitalization | 618M |
|---|---|---|---|---|---|
| Net income 2024 * | -93M | Net income 2025 * | -66M | EV / Sales 2024 * | 23.5 x |
| Net cash position 2024 * | 267M | Net cash position 2025 * | 377M | EV / Sales 2025 * | 24.2 x |
| P/E ratio 2024 * |
-3.52
x | P/E ratio 2025 * |
-6.52
x | Employees | 38 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 39.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cartesian Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +10.43% | ||
| 1 week | +41.31% | ||
| 1 month | +57.32% | ||
| 3 months | +58.21% | ||
| 6 months | -14.27% | ||
| Current year | +67.88% |
1 week
25.37
36.20
1 month
20.5036.20
Current year
11.6736.20
1 year
11.6742.60
3 years
11.6742.60
5 years
11.6742.60
10 years
11.6742.60
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 34.72 | +10.43% | 95,465 |
| 24-05-30 | 31.44 | +8.41% | 96,890 |
| 24-05-29 | 29 | +2.62% | 122,724 |
| 24-05-28 | 28.26 | +15.02% | 130,681 |
| 24-05-24 | 24.57 | -3.50% | 56,326 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
2024-06-14
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
34.72
USD
Average target price
42.6
USD
Spread / Average Target
+22.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +67.88% | 618M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- RNAC Stock
